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ABSTRACT
Colorectal cancer is third leading cause of cancer mortality. About 60% of patients had
already developed metastasis at the time of diagnosis. Vascular endothelial growth factor
(VEGF) is crucial for the development of neovascularization and hence metastasis. This study
aimed at investigating the relation between the expression of VEGF in biopsies from surgi-
cally dissected colon cancer and the survival of those patients. Biopsies were collected from
86 patients with advanced colon cancer and sections were stained by immunohistochemistry
for VEGF. Patients received chemotherapy after the operation and were followed up for
disease progression and survival. The clinical data were statistically analyzed with respect
to the immunohistochemistry results. The survival of the patients was significantly longer in
the patients for whom biopsies showed negative or weak expression of VEGF in comparison
to those with moderate to high expression (p-value = 0.04). The expression of VEGF was more
frequent in the patients who died as a consequence of the disease in comparison to the 10-
year survivors. In conclusion, VEGF could be related to the survival of the patients with
colorectal carcinoma and should be considered as a predictor of the prognosis.
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Colorectal carcinoma is the third most common cause
of cancer related mortality in the world.[1] Targeted
biologic agents have increased the overall median
survival in metastatic colorectal carcinoma (mCRC) to
23.5 months.[2] Kirsten-ras (KRAS) mutations in the
epidermal growth factor receptor (EGFR) pathway
have led to chemotherapy becoming a more perso-
nalized, tailored approach using EGFR monoclonal
antibodies.[3] Different biomarkers were assessed in
numerous studies, but a predictive biomarker for bev-
acizumab has not been identified.[4]
Even after radical surgery and adjuvant chemother-
apy, approximately 50% of colorectal cancer (CRC)
patients subsequently relapse and yield to the dis-
ease.[5] In locally advanced or mCRC, surgical resec-
tion is unlikely to be curative. The five-year survival
rate of metastatic disease is less than 5%.[6] However,
chemotherapy can yield improvements in survival and
is the main treatment modality for the majority of
these patients.[7]
Metastatic disease is the major cause of CRC-
related mortality as a consequence of disease progres-
sion, tumour involvement of critical organs or adverse
events of treatment. The understanding of the growth
and spread of tumours as being dependent on
angiogenesis has opened new avenues of research
to improve knowledge of cancer biology and to facil-
itate the development of new therapeutic strategies.
The process of angiogenesis consists of multiple,
sequential, and interdependent steps with several posi-
tive and negative regulators being involved. The survival
of tumours, and thus their metastases, is dependent
upon a delicate balance between endogenous angio-
genic and anti-angiogenic factors, favouring increased
formation of blood vessels. Neoangiogenesis, the for-
mation of new capillaries from pre-existing blood ves-
sels, is essential for tumour development beyond a
diameter of 2–3 mm3.[8] Angiogenesis provides tumour
cells the opportunity to enter the circulation and thus
the ability to metastasize, in addition to providing nutri-
ents for tumour growth. Angiogenesis is mediated by
angiogenic cytokines.[9] The most potent of these cyto-
kines is vascular endothelial growth factor (VEGF-A), a
heparin-binding glycoprotein with potent angiogenic,
mitogenic, and vascular permeability-enhancing activ-
ities specific for endothelial cells. Of the anti-angiogenic
factors, thrombospondin is of special interest.[10,11]
Evidence from preclinical and clinical studies indicates
that VEGF is the predominant angiogenic factor in human
CRC and is associated with the formation of metastases
and poor prognosis.[12] VEGF is expressed in approxi-
mately 50% of CRCs with minimal to no expression in
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normal colonic mucosa and adenomas. Increased VEGF
expression significantly correlates with advanced lymph
node status and distant metastasis. The survival of
patients with strong VEGF expression is significantly
worse than of those patients with weak or no expres-
sion.[13]
In this study, we examined the expression of VEGF-1
in CRC samples from patients with stage II, III or IV
disease, to determine its association with several clini-
copathological variables, response to treatment and its
influence on disease survival.
2. Subjects and methods
2.1. Patients, treatment and follow-up
The study was approved by the National Authority for
Medico-Legal Affairs Committee and was conducted in
accordance with the declaration of Helsinki. Series of
consecutive histological sections were obtained from
surgically removed biopsies tumours from advanced
CRC patients attending the Department of Oncology
and Radiotherapy, Turku University Hospital, Finland
between August 1998 and August 2003.
The samples were biopsies removed during surgery
from 86 patients with advanced CRC, of whom 55 had
metastases at diagnosis (stage IV disease). The remain-
der, 31, had stage II or III disease at diagnosis. Patients
started treatment at the Department of Oncology and
Radiotherapy, Turku University Hospital between
August 1998 and August 2003. Patient characteristics
are presented in Table 1. An experienced pathologist
confirmed all histological diagnoses.
The patients received a combination of irinotecan
(180–210 mg m–2, administered as a 60–90 min intrave-
nous infusion) and 5-fluorouracil (5-FU) (500 mg m–2, iv
bolus), modulated by folinic acid (FA) (60 mg m–2, iv
bolus). The 5-FU/FA administrations were repeated
again on the following day. This treatment combination
was repeated every two weeks until disease progression
or the occurrence of unacceptable toxicity (Group 2).
Tumour response was assessed every eight weeks
according to WHO criteria, assigned as complete
response, partial response, stable disease and progressive
disease. The study was approved by the National
Authority for Medico-Legal Affairs Committee and was
conducted in accordance with the declaration of Helsinki.
2.2. Immunohistochemical detection of VEGF-1
expression
Formalin-fixed, paraffin-embedded primary tumours
were obtained from 86 patients. The sections were cut
serially at 5 µm for routine haematoxylin and eosin
staining and for immunohistochemical (IHC) analysis.
IHC staining was completed using automated staining
system (DAKO Autostainer, Dako, Copenhagen,
Denmark). Purified anti-human VEGF (121, 165, and
189 isoforms), clone VG-1 (Biosite company, Biosite,
San Diego, CA, USA) (1:150), was used. After staining,
the sections were dehydrated in ethanol, cleared in
xylene and covered with Mountex and coverslips. The
expression of VEGF-1 in the tumour tissue was assessed
blinded to the clinical data, and weighted according to
the expression in the total tumour area. Tumour tissue
showed only cytoplasmic staining. The cytoplasmic
staining was graded into four categories: (0) negative,
no detectable staining; (1) weak but detectable stain-
ing; (2) moderate, clearly positive staining; and (3)
strong staining, intense throughout the tumour.[14]
2.3. Statistical analysis
Statistical analyses were performed using the SPSS
(SPSS, Inc., Chicago, IL, USA) and STATA (Stata Corp.,
College Station, TX, USA) software packages (SPSS for
Windows, version 18.0.1 and STATA/SE 11.1).
Differences in the means of continuous variables
were analysed using non-parametric tests (Mann–
Whitney or Kruskal–Wallis) for two and multiple inde-
pendent samples, respectively. Univariate survival
Table 1. Description of the patients.


















Grade I 11 (12.8%)
Grade II 57 (66.3%)
Grade III 15 (17.4%)
Unknown 3 (3.5)




Location of the primary tumour
Ascending colon 23 (26.7%)
Transverse colon 7 (8.1%)
Descending colon 35 (40.7%)
Rectum 21 (24.4%)




Multiple sites 41 (47.7%)





Died of disease 73 (84.8%)
Unknown 1 (1.2%)





























analysis for the outcome measure (disease-specific
survival [DSS] or disease-free survival [DFS]) was
based on the Kaplan–Meier method, with log-rank
(Mantel–Cox) comparison test. DSS and DFS were
calculated, based on the time from diagnosis to
death (due to disease), and on the time from diagno-
sis to the appearance of metastatic disease, respec-
tively. In all tests, the values p < 0.05 were regarded
statistically significant.
3. Results
VEGF expressions was assessed in all tumours and the
cases were classified as moderate/strong- and nega-
tive/weak expression groups (Figure 1).
The cumulative survival was significantly correlated
with the VEGF expression. Our results showed that
patients with negative to weak VEGF expression had
longer survival with the metastasis in comparison to
the patients with moderate to strong expression (p-
value = 0.04), which could indicate the role of VEGF in
chemoresistance (Figure 2). VEGF expression was
more frequent (61%) among patients who died of
their disease than among the 10-year survivors (49%).
VEGF expression was not statistically associated
with other clinico-pathological variables such as age,
sex, tumor-node-metastasis (TNM) status, grade,
Duke’s stage or carcinoembryonic antigen levels
(data not shown).
4. Discussion
Angiogenesis is a key player in the development of
tumours as well as in metastasis. VEGF enhances the
Figure 2. The cumulative survival of patients with combination therapy group compared according to the expression of VEGF.
(p-value = 0.04).
Figure 1. Examples of VEGF negative (a), weak (b), moderate (c) and strong (d) staining.





























production of new capillaries that supply oxygen and
nutrients to the tumour and provide channels for the
transfer of cancerous cells to distant locations. Such
findings were confirmed in colon cancer. Kondo et al.
[15] showed that VEGF-expressing CRC had increased
vascularity and metastatic potential in comparison to
tumours with baseline VEGF. In addition, accumulating
evidence suggests a prognostic role for VEGF in CRC,
associated with poor prognosis with overexpression.
[13,16–18]
Similarly, a recent meta-analysis by Des Guetz and
colleagues [19] confirms that VEGF expression is asso-
ciated with poor overall survival in CRC. This meta-
analysis included 27 studies specifically investigating
VEGF in CRC, and VEGF expression was shown to be
significantly correlated with poor overall survival and
was a stronger predictor of overall survival than
microvessel density.[19] In the present study, a series
of 360 CRCs comprising all stages of disease (and with
prolonged post-treatment follow up) were analysed
for VEGF expression using IHC approach. Several intri-
guing observations were made, as discussed below.
VEGF seems to be an indicator of poor prognosis in
breast cancer as well and was shown to be correlated
with tumour stage.[20] Similarly, serum VEGF-A levels
have been shown to correlate with disease stage in
CRC, with increasing levels being associated with
more advanced disease.[21] Preoperative serum
VEGF levels have also been shown to correlate with
advanced tumour stage at the time of surgery.[22]
When measured prospectively in a group of patients
undergoing curative resection for CRC, serum VEGF
levels were significantly higher in patients who sub-
sequently developed metastases than in those who
did not.[23,24] Our present observations are fully con-
sistent with these previous reports, confirming that
66.7% of the patients with metastatic disease (stage
IV) have VEGF-positive tumours. Furthermore, VEGF
expression in stage IV tumours was significantly
more intense than in stage II and III disease
(p = 0.005), implicating a direct relationship between
VEGF expression and the stage of the disease; intense
VEGF expression is associated with more advanced
stage and propensity to develop metastatic disease.
Another important observation in the present
study was the close correlation of VEGF expression
with the treatment response; a lower proportion of
patients who clinically benefited from treatment had
VEGF-expressing tumours as compared those who
had progressive disease (49% vs. 61%, respectively,
p = 0.04). This suggests that VEGF expression in the
tumours bears some relationship with the response to
treatment in that VEGF-expressing tumours are less
likely to respond to therapy. Finally, VEGF expression
seems to be of some prognostic value in CRC as
suggested by the present results and some previous
data.[4,13,18,19,25] Ogata and colleagues [26] studied
a series of 342 patients with resected stage II or III
CRC, of whom 225 received adjuvant oral fluoropyr-
imidines and 117 received no further treatment after
surgery, reporting that VEGF overexpression had a
significantly deleterious effect on DFS.[26] This is simi-
lar to the results of another study showing that an
increase in blood vessel count and VEGF concentra-
tion correlated with progression and metastases of
CRC.[19] In yet another study, both overall and DFS
were found to be significantly lower in patients with
VEGF-positive tumours.[25] In the present study, we
are reporting a significant correlation between VEGF
expression in colorectal tumour biopsies and patient
survival, which can open the door for the use of VEGF
in clinical perspective.
5. Conclusion
VEGF expression was clearly accentuated in
advanced disease stages, implicating an effect on
the propensity to develop a metastatic phenotype.
Furthermore, VEGF expression was shown to be rarer
among patients who showed clinical benefit of
treatment as compared to those who had progres-
sive disease, suggesting that VEGF expression might
make the tumour cells more resistant to therapy.
Finally, VEGF expression in the primary tumours
seems to be associated with less favourable long-
term (10-year) survival as compared with VEGF-
negative tumours, possibly implicating some differ-
ences in the inherent malignancy of CRC that only
become manifest after prolonged follow-up.
Numerous retrospective studies showed the
prognostic value of VEGF expression in CRC. High
VEGF expression in tumour tissue indicated a
shorter relapse free survival and overall survival.
[19] Further studies are still needed to verify the
role of VEGF as a predictive biomarker for the effi-
cacy of antiangiogenic therapy.[4] Jalbă et al. [27]
showed that VEGF-A expression was a poor prog-
nostic marker for CRC. In another study; Pohl et al.
[28] found no correlation between treatment
response and VEGF expression within the tumour
tissue. In our study we found longer overall survival
rates with negative VEGF expression, which may
indicate a role for VEGF in CRC from a clinical
perspective. Further studies may lead to considera-
tion of VEGF status for CRC patients as a part of
their management plan, aiming at personalized
treatment as well as prediction of progress.
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